Tkacheva O N, Akasheva D U
Ter Arkh. 2014;86(4):103-7.
It is well known that there is a 5-fold increase in the incidence of strokes and systemic thromboembolic events in atrial fibrillation (AF) and anticoagulant therapy considerably reduces the risk of their development. Until recently, warfarin has been mainly used for this purpose. Dabigatran is the first representative of new-generation oral anticoagulants from a class of direct thrombin inhibitors to treat nonvalvular AF. Unlike warfarin, the drug provides a predictable and steady-state anticoagulant effect. This review presents the main pharmacological characteristics of dabigatran, the possibilities of its use in complex clinical situations in patients with AF in cardioversion, ablation, surgical/invasive interventions, hemorrhage, myocardial infarction, and stroke, as well as data on the use of the drug in real clinical practice.
众所周知，心房颤动（AF）患者中风和全身性血栓栓塞事件的发生率会增加5倍，而抗凝治疗可显著降低其发生风险。直到最近，华法林一直主要用于此目的。达比加群是新一代口服抗凝剂中直接凝血酶抑制剂类的首个代表药物，用于治疗非瓣膜性AF。与华法林不同，该药物可提供可预测的稳态抗凝效果。本综述介绍了达比加群的主要药理学特性、其在AF患者进行心脏复律、消融、手术/侵入性干预、出血、心肌梗死和中风等复杂临床情况下的使用可能性，以及该药物在实际临床实践中的使用数据。
